Scarica l'app Stockscreener
16.70
3.21%
0.52
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$16.18
Aprire:
$16.28
Volume 24 ore:
8.92M
Relative Volume:
0.84
Capitalizzazione di mercato:
$19.45B
Reddito:
$14.57B
Utile/perdita netta:
$-296.50M
Rapporto P/E:
-64.48
EPS:
-0.259
Flusso di cassa netto:
$1.64B
1 W Prestazione:
+3.92%
1M Prestazione:
+6.44%
6M Prestazione:
+34.03%
1 anno Prestazione:
+78.80%
Intervallo 1D:
$16.27
$16.74
Intervallo di 1 settimana:
$15.79
$16.74
Portata 52W:
$8.625
$17.53
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, HLN, TEVA, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
16.70 | 18.49B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
16.77 | 50.65B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.82 | 41.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.64 | 39.45B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
74.80 | 30.13B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
555.91 | 23.00B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Aggiornamento | UBS | Neutral → Buy |
| 2026-01-16 | Aggiornamento | Argus | Hold → Buy |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Form 4 Viatris Inc For: 1 July By Investing.com - Investing.com Canada
Viatris (VTRS) director David S. Simmons granted 2,362 deferred stock units as fees - Stock Titan
Viatris (VTRS) director takes 2,756 deferred stock units instead of cash fees - Stock Titan
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
ViatrisEnters Amended And Restated Term Loan Credit Agreement On July 1, 2026SEC Filing - TradingView
Viatris Secures ¥40 Billion Three-Year Term Loan With Mizuho to Refinance 2021 Facility - TradingView
Viatris (NASDAQ: VTRS) signs ¥40B three-year unsecured term loan deal - Stock Titan
Viatris to Report Second-Quarter 2026 Financial Results on August 6, 2026 - BioSpace
The Bull Case For Viatris (VTRS) Could Change Following Positive Japan Phase 3 Data For VR-205 - simplywall.st
VTRSViatris Inc Latest SEC Filings - Finviz
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Securities Fraud Class Action Filed Against Viatris Inc. (VTRS) Levi & Korsinsky Reminds Investors of June 3, 2025 - The National Law Review
Viatris reports positive phase 3 results for IgAN drug in Japan By Investing.com - Investing.com India
(VTRS) Risk Channels and Responsive Allocation - Stock Traders Daily
How is Viatris’ stock performance compared to other healthcare stocks? - MSN
Viatris reports positive Japanese phase 3 results for Nefecon in IgAN - MSN
Viatris reports positive phase 3 results for IgAN drug in Japan - Investing.com South Africa
Viatris' VR-205 Meets Primary, Key Secondary Endpoints in Japanese Phase 3 Trial in Kidney Disease - marketscreener.com
Viatris (VTRS) Reports Positive Phase 3 Trial Results for VR-205 - GuruFocus
Viatris Announces Positive Top-Line Results from Phase 3 Study of VR-205 in Japanese Adults with Primary Immunoglobulin A Nephropathy - PR Newswire
Join Class Action to Recover Losses from Viatris Inc. (VTRS)Contact Levi & Korsinsky Before June 3, 2025 - The National Law Review
Enterprise value to EBITDA forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris interim CFO Paul Campbell sells $809,784 in stock By Investing.com - Investing.com South Africa
Viatris interim CFO Paul Campbell sells $809,784 in stock - Investing.com UK
Form 4 Viatris Inc For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Planned sale: Viatris (VTRS) officer disposes 50,076 shares - Stock Titan
Viatris | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Viatris, Inc. Actuals & Estimates (FWB:VIA) - TradingView
Price to sales forward of Viatris Inc. – NASDAQ:VTRS - TradingView
Viatris, Inc. Actuals & Estimates (SWB:VIA) - TradingView
Viatris, Inc. Actuals & Estimates (BMV:VTRS) - TradingView
Viatris Inc (VTRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Viatris, Inc. Actuals & Estimates (DUS:VIA) - TradingView
Form 144 Viatris Inc For: 25 June By Investing.com - Investing.com Nigeria
Viatris (VTRS) Rule 144 notice lists 49,715 vested shares and other entries - Stock Titan
VTRS Forecast — Price Target — Prediction for 2027 - TradingView
How Viatris’ €650 Million Eurobond Issue (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS) - Seeking Alpha
Are Investors Undervaluing Viatris (VTRS) Right Now? - Yahoo Finance
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc. (VTRS) Investor Outlook: Is The 15.89% Potential Upside Worth The Risk? - DirectorsTalk Interviews
Come As You Are: Emily Smith Builds Solidarity, Support for LGBTQ+ Colleagues Through VIVID - CSRwire
How Is Viatris’ Stock Performance Compared to Other Healthcare Stocks? - Barchart.com
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris Issues €650 Million Senior Notes to Refinance Debt - TipRanks
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):